SANDOZ PAZOPANIB TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

PAZOPANIB (PAZOPANIB HYDROCHLORIDE)

可用日期:

SANDOZ CANADA INCORPORATED

ATC代码:

L01EX03

INN（国际名称）:

PAZOPANIB

剂量:

200MG

药物剂型:

TABLET

组成:

PAZOPANIB (PAZOPANIB HYDROCHLORIDE) 200MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

ANTINEOPLASTIC AGENTS

產品總結:

Active ingredient group (AIG) number: 0152743001; AHFS:

授权状态:

APPROVED

授权日期:

2021-10-15

产品特点

_Sandoz Pazopanib (pazopanib hydrochloride) Product Monograph _
_Page 1 of 55_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR SANDOZ PAZOPANIB
Pazopanib tablets
Tablets, 200 mg pazopanib (as pazopanib hydrochloride), oral
Antineoplastic Agent
Sandoz Canada Inc.
110, De Lauzon
Boucherville, Quebec
J4B 1E6
www.sandoz.ca
Date of Initial Authorization:
October 15, 2021
Date of Revision:
June 29, 2022
Submission Control Number: 261636
®
Registered trademark used under license
_ _
_Sandoz Pazopanib (pazopanib hydrochloride) Product Monograph _
_Page 2 of 55_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Cardiovascular
06/2022
7 WARNINGS AND PRECAUTIONS, Combinations with other systemic
anti-cancer therapies
06/2022
7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics
06/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
5
2
CONTRAINDICATIONS
.................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
6
4.1
Dosing Considerations
..........................................